Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

被引：0

作者：

Hui Yu

Ping Chen

Xiuyu Cai

Chen Chen

Xuanye Zhang

Lina He

Yixin Zhou

Shaodong Hong

Bei Zhang

机构：

[1] State Key Laboratory of Oncology in South China,Department of VIP Region

[2] Collaborative Innovation Center for Cancer Medicine,Department of Radiotherapy

[3] Sun Yat-Sen University Cancer Center,Department of Medical Oncology

[4] Sun Yat-Sen University Cancer Center,undefined

[5] Sun Yat-Sen University Cancer Center,undefined

来源：

Cancer Immunology, Immunotherapy | 2022年 / 71卷

关键词：

PD-L1 inhibitors; PD-1 inhibitors; Small-cell lung cancer; First-line therapy; Efficacy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：637 / 644

页数：7

共 50 条

[11] Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
Facchinetti, Francesco
Di Maio, Massimo
Tiseo, Marcello
CANCERS, 2020, 12 (09) : 1 - 18
[12] Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study
Tian, Yaru
Lu, Shuangqing
Sun, Yulan
Tang, Xiaoyong
Sun, Zhuoran
Zhao, Ke
Du, Guochang
Li, Wanjing
Zhu, Hui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[13] A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer
Fu, Jie
Yan, Yi-Dan
Wan, Xu
Sun, Xiao-Fan
Ma, Xiu-Mei
Su, Ying-Jie
FRONTIERS IN PHARMACOLOGY, 2025, 15
[14] Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study.
Tian, Yaru
Lu, Shuangqing
Sun, Yulan
Tang, Xiaoyong
Sun, Zhuoran
Zhao, Ke
Du, Guochang
Li, Wanjing
Zhu, Hui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 206 - 206
[15] Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
Li, Xiang
Yan, Shi
Yang, Jichun
Wang, Yaqi
Lv, Chao
Li, Shaolei
Zhao, Jun
Yang, Yue
Zhuo, Minglei
Wu, Nan
FRONTIERS IN ONCOLOGY, 2021, 10
[16] Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer
Lu, Jiangyue
Lei, Xiao
Zhang, Pei
Du, Lehui
Zhang, Zhibo
Qu, Baolin
CANCER MEDICINE, 2023, 12 (17): : 17924 - 17933
[17] Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study
Xie, Jingyuan
Xu, Ke
Cai, Zijing
Chen, Mo
Jiang, Yuxin
Ye, Jinjun
Lin, Xinqing
Lv, Tangfeng
Zhan, Ping
TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (03) : :526 - 539
[18] Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer
Yu, Lian
Xu, Jianlin
Qiao, Rong
Han, Baohui
Zhong, Hua
Zhong, Runbo
CANCER MEDICINE, 2023, 12 (05): : 5372 - 5383
[19] Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study
Xie, Jingyuan
Chen, Mo
Han, Hedong
Xu, Ke
Qiu, Guihuan
Lin, Xinqing
Song, Yong
Ye, Jinjun
Lv, Tangfeng
Zhan, Ping
THORACIC CANCER, 2023, 14 (15) : 1327 - 1338
[20] A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.
Chen, Size
Lin, Yiguang
Song, Minghan
Dong, Jiayi
Lijuan, Shao
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →